Dr Parr joined Targanta as Chief Scientific Officer in January 2005. Prior to that, Dr. Parr has been at Lilly Research Laboratories for ten years and also with several other anti-infective companies including Microcide, Intrabiotics, Embiosis, and most recently Adaptive Therapeutics where he was Vice President of Research. He has been involved in the development of several marketed and late-stage clinical candidates for both antibacterial and antifungal applications. Dr. Parr received his Ph.D. degree from The University of Calgary. He was a postdoctoral fellow at The University of British Columbia, and a member of the faculty at The University of Ottawa before beginning his industrial career.